Stratos Wealth Partners LTD. Has $1.80 Million Position in CVS Health Corporation $CVS

Stratos Wealth Partners LTD. lowered its stake in CVS Health Corporation (NYSE:CVS) by 3.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,113 shares of the pharmacy operator’s stock after selling 964 shares during the period. Stratos Wealth Partners LTD.’s holdings in CVS Health were worth $1,801,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Jennison Associates LLC grew its holdings in CVS Health by 503.8% during the 1st quarter. Jennison Associates LLC now owns 1,896,341 shares of the pharmacy operator’s stock worth $128,477,000 after acquiring an additional 1,582,257 shares during the period. Cantor Fitzgerald Investment Advisors L.P. grew its holdings in CVS Health by 1.6% during the 2nd quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 409,735 shares of the pharmacy operator’s stock worth $28,264,000 after acquiring an additional 6,615 shares during the period. Cerity Partners LLC grew its holdings in CVS Health by 25.0% during the 1st quarter. Cerity Partners LLC now owns 648,266 shares of the pharmacy operator’s stock worth $43,920,000 after acquiring an additional 129,535 shares during the period. Bank of New York Mellon Corp grew its holdings in CVS Health by 2.1% during the 1st quarter. Bank of New York Mellon Corp now owns 8,981,262 shares of the pharmacy operator’s stock worth $608,481,000 after acquiring an additional 183,813 shares during the period. Finally, Brandywine Global Investment Management LLC grew its holdings in CVS Health by 20.1% during the 1st quarter. Brandywine Global Investment Management LLC now owns 3,421,519 shares of the pharmacy operator’s stock worth $231,808,000 after acquiring an additional 572,533 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Down 0.1%

CVS opened at $82.47 on Tuesday. The stock has a market capitalization of $104.59 billion, a P/E ratio of 23.04, a P/E/G ratio of 0.91 and a beta of 0.60. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $82.88. The firm’s fifty day simple moving average is $74.35 and its 200 day simple moving average is $68.25. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, beating the consensus estimate of $1.46 by $0.35. The business had revenue of $98.92 billion for the quarter, compared to analysts’ expectations of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The firm’s revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Thursday, October 23rd will be given a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s payout ratio is currently 74.30%.

Insider Buying and Selling

In related news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the sale, the director directly owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.22% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Leerink Partners lifted their target price on shares of CVS Health from $86.00 to $95.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Jefferies Financial Group lifted their price target on shares of CVS Health from $80.00 to $92.00 in a research report on Wednesday, October 15th. Wolfe Research lifted their price target on shares of CVS Health from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Bernstein Bank reduced their price target on shares of CVS Health from $78.00 to $72.00 and set a “market perform” rating on the stock in a research report on Wednesday, July 16th. Finally, Sanford C. Bernstein lifted their price target on shares of CVS Health from $72.00 to $77.00 and gave the stock a “market perform” rating in a research report on Friday, September 5th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $82.57.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.